For individuals who are not suffering from diabetes but aim at losing weight through medication, the use of FDA-approved medications such as Wegovy (semaglutide) or Zepbound (tirzepatide) would work effectively compared to using Farxiga, which helps in losing only 2-3% body weight compared to the Semaglutide alternatives which are 12-20% achievable by FDA-approved medications
The drug combination was generally well tolerated, with side effects consistent with the known profiles of the individual drugs
Always talk to your doctor before making any changes to your treatment
Advancements in next-generation sequencing and protein expression profiling have demonstrated that the renal targets of thiazides, i.e., Na + Cl cotransporter (NCC, encoded by SLC12A3 ) and that of bumetanide/furosemide, i.e., Na + K + 2Cl cotransporter-2 (NKCC2, encoded by SLC12A1 ) are expressed in different tissues and cells, albeit at lower levels (Di Fulvio and Alvarez-Leefmans, 2009)